Publication & Citation Trends
Publications
0 total
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.
Cited by 1
Semantic Scholar
LISOCABTAGENE MARALEUCEL IN R/R FL (TRANSCEND FL): IMPACT OF PRIOR LINES OF THERAPY, BENDAMUSTINE EXPOSURE, AND DISEASE PROGRESSION ≤ 24 MONTHS OF INITIAL SYSTEMIC THERAPY
Cited by 0
Semantic Scholar
Evaluating the utility of endogenous OCT2 and MATE1/2-K biomarkers for DDI assessment in early clinical settings.
Cited by 2
Semantic Scholar
POSTER: CT-235 Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24)
Cited by 0
Semantic Scholar
LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL) IN THE PHASE 2 TRANSCEND FL STUDY
Cited by 2
Semantic Scholar
CT-235: Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24)
Cited by 0
Semantic Scholar
POSTER: CT-230 Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study
Cited by 0
Semantic Scholar
CT-230: Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study
Cited by 0
Semantic Scholar
Research Topics
Acute Lymphoblastic Leukemia research
(23)
Lymphoma Diagnosis and Treatment
(15)
Acute Myeloid Leukemia Research
(7)
Childhood Cancer Survivors' Quality of Life
(7)
Chronic Lymphocytic Leukemia Research
(7)
Affiliations
Tokyo Medical and Dental University
St. Jude Children's Research Hospital
University of South Australia
Laboratory of Molecular Genetics
Bristol-Myers Squibb (United States)